NCT04697953View on ClinicalTrials.gov

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2021

Primary Completion Date

June 21, 2021

Study Completion Date

May 31, 2025

Conditions
Age-related Macular Degeneration (AMD)
Interventions
DRUG

brolucizumab

Pre-filled Syringes for intravitreal injection

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT04697953 - Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) | Biotech Hunter | Biotech Hunter